KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Deferred Taxes (2016 - 2019)

Historic Deferred Taxes for Arbutus Biopharma (ABUS) over the last 5 years, with Q3 2019 value amounting to -$12.7 million.

  • Arbutus Biopharma's Deferred Taxes fell 19567.96% to -$12.7 million in Q3 2019 from the same period last year, while for Dec 2020 it was -$12.7 million, marking a year-over-year increase of 2527.3%. This contributed to the annual value of -$12.7 million for FY2019, which is 19567.96% down from last year.
  • According to the latest figures from Q3 2019, Arbutus Biopharma's Deferred Taxes is -$12.7 million, which was down 19567.96% from -$4.3 million recorded in Q3 2018.
  • Arbutus Biopharma's Deferred Taxes' 5-year high stood at -$989000.0 during Q4 2015, with a 5-year trough of -$64.9 million in Q2 2016.
  • Its 5-year average for Deferred Taxes is -$23.2 million, with a median of -$15.2 million in 2015.
  • Its Deferred Taxes has fluctuated over the past 5 years, first plummeted by 396440.85% in 2016, then skyrocketed by 3949.8% in 2017.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Deferred Taxes stood at -$989000.0 in 2015, then plummeted by 3964.41% to -$40.2 million in 2016, then soared by 39.5% to -$24.3 million in 2017, then surged by 82.39% to -$4.3 million in 2018, then tumbled by 195.68% to -$12.7 million in 2019.
  • Its Deferred Taxes was -$12.7 million in Q3 2019, compared to -$4.3 million in Q3 2018 and -$24.3 million in Q4 2017.